Arterial stiffness and COVID-19: A bidirectional cause-effect relationship

1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19) primarily affects the lungs but the clinical manifestations vary markedly among the patients involved. In more severe cases, COVID-19 can lead to acute respiratory distress syndrome (ARDS), multi-organ failure including cardiac injury and toxic shock syndrome with need for intensive care and a ventilator support, while at the opposite extreme the signs and symptoms can be those of a mild flu and in many patients the infection is asymptomatic.

Since the outbreak of the infection in China, a large number of studies have consistently reported on the cardiovascular (CV) complications of COVID-19 which include acute cardiac injury, cardiac arrhythmias, and diffuse endothelial damage leading to microvascular thrombosis and thromboembolic events. Evidence has also consistently suggested that cardiac, vascular, renal, and cerebral damages associated with CV risk factors such as hypertension, diabetes, dyslipidemias, and obesity markedly increase the risk of COVID-19 progression to its most severe and lethal forms, presumably because the pre-existing structural and functional alterations of the organs affected by long-lasting blood pressure elevation and metabolic alterations weaken their resistance to the virus. Resistance to the virus may be further reduced by the pathogenetic nature of some of these organ alterations, that is, by the fact the most common cause of risk factor-dependent complications, atherosclerosis, is likely to be co-determined by an inflammatory process that may adversely interact with that of the coronavirus. As far as obesity, a major component of the metabolic syndrome, is concerned, its relationship with the COVID-19 severity may be due to its association with chronic low grade inflammation, higher leptin and lower adiponectin levels, immune response dysregulation, and abnormal pro-inflammatory cytokine production.

The association between increased arterial stiffness and the severity and duration of chronic inflammation in a number of systemic inflammatory diseases are well established. The vascular structure and function are altered by edema and inflammatory cells. Prior studies have supported the cross talk between inflammation and arterial stiffness by showing that patients with chronic inflammatory diseases such as rheumatoid arthritis and chronic inflammatory bowel disease have higher arterial stiffness than control subjects matched for age, sex and blood pressure. Hence, the severity of underlyng chronic inflammation in these disease states goes hand-in-hand with the severity of arterial stiffness. For all these interactive factors, there is the basis for a vicious circle because, by increasing the traumatic effect of intravascular pulsatile pressure on the vascular wall, arterial stiffening favors atherosclerosis with an increase in its inflammatory component and a further stiffening effect. The same may be true for COVID-19. COVID-19 is a multisystem disease with hyperinflammation and altered immune response and may therefore have detrimental effects on the systemic vasculature both on short and long run. A practical example may be the ethnic minorities who experience the more aggressive forms of COVID-19 with an enhanced systemic inflammatory response and higher rates of CV complications. Of note, these patients have a substantial higher prevalence of pre-existing hypertension, obesity, and diabetes, a cluster which is associated with systemic inflammation and may weaken the resistance of target organs against the coronavirus.

During the COVID-19 pandemic, CV research has reserved little attention to vascular damage such as increased large artery stiffness. This has little justification because large artery stiffening has been repeatedly shown to have a paramount clinical importance because it: 1) predicts future progression to hypertension in people who exhibit a normal BP; 2) increases the long-term risk of future events and death, independently on the contribution of other risk factors; and 3) favors damage of organ structure and function by increasing pulsatile flow transmission to the microvasculature. The possibility that large artery stiffening is part of the CV phenotype of COVID-19 is also supported by the evidence that some factors which are known to operate during the COVID-19 disease are known to adversely affect large artery distensibility, which will be discussed below.

2 | PREVIOUS WORK

During the COVID-19 pandemic, there have been so far only few small studies assessing the impact of COVID-19 on arterial stiffness (Table 1). As an initial contribution to the field, Schnaubelt...
TABLE 1  Overview of the studies assessing arterial stiffness and function in COVID-19

| First author (reference no) | Mean age | Number of patients and controls | Design | Method for assessment of vascular health | Major findings |
|-----------------------------|----------|---------------------------------|--------|----------------------------------------|---------------|
| Schnaubelt et al [9]        | 76.5 years | 22 COVID-19 patients, 22 non-COVID-19 controls | Case control | Brachial-ankle and carotid-femoral PWV | COVID-19 patients had higher PWV than controls (14.3 m/s vs. 11.0 m/s, P = .007). In COVID-19 survivors (n = 11), PWV correlated with the length of hospital stay (mean 12.6 ± 4.3 days). PWV was higher in non-survivors of COVID-19 than in COVID-19 survivors. |
| Ratchford et al [10]        | COVID-19: 20 years, Control: 23 years | 11 COVID-19 patients, 20 controls | Cross-sectional Case control | Brachial FMD Leg sPLM Carotid-femoral PWV | COVID-19 patients had impaired vascular function and higher arterial stiffness compared with control group: - lower FMD of the brachial artery (2.71 ± 1.21% vs. 8.81 ± 2.96%, P < .01), - higher carotid-femoral PWV (5.83 ± 0.62 m/s vs. 5.17 ± 0.66 m/s, P < .01) |
| Rodilla et al [11]          | 67.5 years | 12 170 patients (2606 non-survivors, 9564 survivors) | Retrospective All-cause mortality at 50 days | Admission pulse pressure ≥ 60 mmHg | Increased arterial stiffness (admission pulse pressure ≥ 60 mmHg) was associated with higher risk for all-cause mortality in COVID-19 patients (adjusted odds ratio 1.27, P = .0001) |

Abbreviations: FMD, flow-mediated dilation; PWV, pulse wave velocity; sPLM, single passive limb movement.
increasing the matrix metalloproteinase levels and leading to functional and structural arterial remodeling.\textsuperscript{18} Indeed, large artery stiffening may in principle be one of the COVID-19 damages with a greater chance to persist after recovery from COVID-19, a sequela that may materialize if the post-infection fibrosis that has been documented in the lungs extends to the vascular wall tissue, that is, if in the large artery wall fibrosis replaces the elastic tissue component. The potential mechanisms that may adversely affect arterial function and structure in COVID-19 disease are shown in Figure 1.

Another possible mechanism is the modification of the arterial wall tissue brought about by the cytokine-dependent increase of inflammatory cells and of the inflammatory edema, given the repeated demonstration of a close relationship between arterial stiffness and the severity and duration of chronic inflammation in a number of systemic inflammatory diseases.\textsuperscript{3,4} Systemic cytokine storm as result of an aggressive systemic inflammation in COVID-19 and dysregulation of immune response have gained much attention during the pandemic.\textsuperscript{1} This may also lead to endothelial dysfunction, increased oxidative stress, decreased nitric oxide secretion and bioavailability, decreased relaxation of smooth muscle cells and vasoconstriction with an increase in the elastic modulus compared to the relaxed state. Increased blood viscosity due to hyperglycemia, hypoxia, disseminated intravascular coagulation (DIC), and enhanced fibrinogen degradation products are other contributing factors (Figure 1).\textsuperscript{19} Upregulation of inflammatory cytokines such as tumor necrosis factor alpha (TNF-\(\alpha\)) and interleukins (ILs) (IL-6 and IL-8), enhance platelet reactivity and activation of leukocytes to form neutrophil extracellular traps (NETs) which further contributes to a pro-thrombotic state and formation of microvascular thrombi.\textsuperscript{20,21} IL-6 also causes detrimental endothelial activation which increases vascular permeability through nitric oxide.\textsuperscript{15}

Other theories such as SARS-CoV-2 infection-related mitochondrial dysfunction and increase inmitochondrial reactive oxygen species (ROS) production have also been proposed.\textsuperscript{22} Mitochondrial ROS functions as signaling molecule keeping basal vascular hemostasis and inflammatory pathways in balance. Enhanced ROS production by dysfunctional mitochondria leads to oxidative stress and promotion of inflammation and chronic endothelial dysfunction with subsequent CV disease and lung injury after recovery from COVID-19 have also been proposed.\textsuperscript{22} It has been also postulated that mitochondrial ROS may induce premature aging through oxidative telomere damage.\textsuperscript{22}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{The bidirectional association between baseline increased arterial stiffness and target organ damage, and COVID-19 severity. Both target organ damage and COVID-19 disease severity share the same risk factors. Through a number of possible mechanisms, COVID-19 can cause short term functional and structural remodeling of the vascular wall. However, the long-term effects are yet to be seen. CV, cardiovascular; cf-PWV, carotid-femoral pulse wave velocity; FMD, flow-mediated dilation; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; NO, nitric oxide; RAAS, renin-angiotensin-aldosterone system; SMC, smooth muscle cell; TNF-\(\alpha\), tumor necrosis factor alpha.}
\end{figure}
4 | THE ROLE OF PRE-EXISTING ATHEROSCLEROSIS/INCREASED ARTERIAL STIFFNESS IN COVID-19 SEVERITY

In atherosclerosis, that is, the most important intermediate step between CV risk factors and CV morbidity and fatal events, endothelial cells are damaged and the blood flow patterns are irregular. These lead to subendothelial plasma lipoprotein (LDL) deposition and oxidation, plaque formation, and narrowing of the artery lumen. Pre-existing atherosclerosis is an independent risk factor for COVID-19 severity, which is evident from the studies reporting higher mortality in COVID-19 patients with underlying CV risk factors and morbidities. Vinciguerra et al hypothesized that in COVID-19 patients with pre-existing atherosclerosis, an immune system dysregulation favors SARS-CoV-2 entry into human cells. However, atherosclerosis may also be a long-term consequence of COVID-19 by activation and initiation of chronic vascular endothelial dysfunction. Data from the UK Biobank have recently demonstrated that COVID-19-positive individuals who died had significantly lower left ventricular stroke volume, more often impaired global longitudinal strain (GLS), and lower arterial compliance (lower aortic distensibility and higher arterial stiffness index) compared to those who survived.

5 | POST-COVID-19 EARLY ATHEROSCLEROSIS/INCREASED ARTERIAL STIFFNESS

Whether COVID-19 patients are predisposed to early atherosclerosis is not yet fully understood. However, it is reasonable to believe that post-COVID-sequelae such as worsening of hypertension, diabetes, renal damage, and inflammation-induced dyslipidemia (altered lipid metabolism) and endothelial dysfunction may contribute to early atherosclerosis and accelerate vascular aging. Furthermore, sympathetic nerve activity, dysregulation of the RAS, altered ACE-2 expression may lead to adverse structural and functional remodeling of the arteries, and therefore, a bidirectional association between pre-existing arterial stiffness and COVID-19 severity, as well as post-COVID increase in arterial stiffness, can be seen (Figure 1). Even lack of physical activity and psychological stress during lockdown may be important functional modulators of arterial stiffness. Hence, increased arterial stiffness at baseline due to age or CV risk factors and comorbidities is associated with more severe COVID-19 disease, and COVID-19 per se may be associated with further acceleration of arterial stiffening (arterial sclerosis) or development of early atherosclerosis. Although some preliminary reports, as mentioned earlier, support these speculations, this need to be proven in future studies, and is of great clinical importance for public health in terms of early detection and prevention of atherosclerosis and reducing the risk of early vascular events such as coronary artery disease and stroke in these vulnerable patients.

Statin lower CV risk factors through their lipid-lowering and pleiotropic or anti-inflammatory effects. It has been also postulated that statin may act as a SARS-CoV-2 main protease inhibitor. Some preliminary reports have shown that use of statin in COVID-19 patients is associated with improved survival rate although this also requires further validation in other studies. Furthermore, the role of anti-inflammatory drugs such as colchicine, nitric oxide, and heparin in COVID-19 patients will be explored by some ongoing studies.

6 | CONCLUSION

There appears to be a bidirectional association between arterial stiffness/atherosclerosis and COVID-19 severity. Preliminary studies have already documented the association of COVID-19 with adverse functional and morphological changes in the arterial wall. Endothelial damage by direct invasion of the coronavirus or through inflammation-induced systemic cytokine storm is believed to be a key element in the pathogenesis of COVID-19-related target arterial damage.

7 | PERSPECTIVES

We should acknowledge that this opinion piece is prepared from a clinical point of view and hence hypothesis generating. The molecular mechanism is not discussed, although these are still poorly understood. Therefore, larger prospective studies with assessment of arterial stiffness in patients with or without prior COVID-19 infection should be performed to gain more information on the acute and chronic impact of COVID-19 infection on systemic vasculature, particularly in terms of developing early atherosclerosis or an unsuccessful early vascular aging. The establishment of larger collaborative projects is essential to examine the long-term vascular consequences of COVID-19 and reduce the risk of vascular events in COVID-19 survivors. Hopefully, future longitudinal studies will also examine the diagnostic impact of baseline left ventricular hypertrophy and increased PWV in COVID-19 patients. There are very limited blood pressure data, particularly involving ambulatory blood pressure monitoring after recovery from COVID-19. This should be the focus of future vascular research in COVID-19.

ACKNOWLEDGEMENT
None.

CONFLICT OF INTEREST
No conflict of interest.

AUTHOR CONTRIBUTIONS
Sahrai Saeed and Giuseppe Mancia contributed to the conception of this work. Sahrai Saeed wrote the first draft. Giuseppe Mancia critically revised it for important intellectual. Both authors approved the final submission.
Zanoli L, Boutouyrie P, Fatuzzo P, et al. Inflammation and aortic stiffness.

Kaess BM, Rong J, Larson MG, et al. Aortic stiffness, blood pressure, and cardiovascular disease.

Mitchell GF. Arterial stiffness and hypertension: chicken or egg?

Ratchford SM, Stickford JL, Province VM, et al. Vascular alterations among young adults with SARS-CoV-2.

Schnaubelt S, Oppenauer J, Tihanyi D, et al. Arterial stiffness in COVID-19: a novel pathophysiological role for inflammation.

Chiappetta S, Sharma AM, Bottino V, et al. COVID-19 and the role of acute COVID-19 and potential associations with clinical outcome.

Sahrai Saeed MD, PhD, FESC
Giuseppe Mancia MD, PhD

1Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
2University of Milano-Bicocca, Milano and Policlinico di Monza, Monza, Italy

Correspondence
Sahrai Saeed MD, PhD, FESC, Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.
Email: sahari.saeed@helse-bergen.no

ORCID
Sahrai Saeed https://orcid.org/0000-0003-4041-5019

REFERENCES
1. Saeed S, Tadic M, Larsen TH, et al. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. Journal Hypertens. 2021. https://doi.org/10.1097/JHJ.000000000002819. Online ahead of print.
2. Chiappetta S, Sharma AM, Bottino V, et al. COVID-19 and the role of chronic inflammation in patients with obesity. Int J Obes (Lond). 2020;44:1790-1792.
3. Zanoli L, Briet M, Empana JP, et al. Association for research into arterial structure, physiology (ARTERY) society, the european society of hypertension (ESH) working group on vascular structure and function, and the european network for noninvasive investigation of large arteries. vascular consequences of inflammation: a position statement from the ESH working group on vascular structure and function and the ARTERY society. J Hypertens. 2020;38:1682-1698.
4. Zanoli L, Boutouyrie P, Fatuzzo P, et al. Inflammation and aortic stiffness: an individual participant data meta-analysis in patients with inflammatory bowel disease. J Am Heart Assoc. 2017;6(10):e007003.
5. Vepa A, Bae JP, Ahmed F, et al. COVID-19 and ethnicity: A novel pathophysiological role for inflammation. Diabetes Metab Syndr. 2020;14:1043-1051.
6. Liao D, Arnett DK, Tyroler HA, et al. Arterial stiffness and the development of hypertension: the ARIC study. Hypertension. 1999;34:201-206.
7. Kaess BM, Rong J, Larson MG, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308:875-881.
8. Mitchell GF. Arterial stiffness and hypertension: chicken or egg? Hypertension. 2014;64:210-214.
9. Schnaubelt S, Oppenauer J, Tihanyi D, et al. Arterial stiffness in acute COVID-19 and potential associations with clinical outcome. J Intern Med. 2021. https://doi.org/10.1111/joim.13275. Online ahead of print.
10. Ratchford SM, Stickford JL, Province VM, et al. Vascular alterations among young adults with SARS-CoV-2. Am J Physiol Heart Circ Physiol. 2021;320:H404-H410.
11. Rodilla E, López-Carmona MD, Cortes X, et al. SEMI-COVID-19 network. Impact of arterial stiffness on all-cause mortality in patients hospitalized with COVID-19 in Spain. Hypertension. 2021;77:856-867.
12. Wasim D, Alme BA, Jordal S, et al. Characteristics of the 24-hour ambulatory blood pressure monitoring in a COVID-19 survivor. Future Cardiol. https://doi.org/10.2217/fca-2020-0235. In press.
13. Nägële MP, Haubner B, Tanner FC, et al. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62.
14. Kaur S, Tripathi DM, Yadav A. The Enigma of Endothelium in COVID-19. Front Physiol. 2020;11:989.
15. Pearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;24:723-730.
16. Sardu C, Gambardella J, Morelli MB, et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? a comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9:1417.
17. Liu Y, Zhang HG. Vigilance on new-onset atherosclerosis following SARS-CoV-2 infection. Front Med (Lausanne). 2021;20(7):629413.
18. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418.
19. Hess DC, Eldahshan W, Rutkowski E. COVID-19-related stroke. Transl Stroke Res. 2020;11:322-325.
20. Engellmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45.
21. Lou M, Yuan D, Liao S, et al. Potential mechanisms of cerebrovascular diseases in COVID-19 patients. J Neurovirol. 2021;27:35-51.
22. Chang R, Mamun A, Dominic A, et al. SARS-CoV-2 mediated endothelial dysfunction: the potential role of chronic oxidative stress. Front Physiol. 2021;15(11):605908.
23. Vinciguerra M, Romiti S, Fatouch K, et al. Atherosclerosis as pathogenetic substrate for Sars-Cov2 cytokine storm. J Clin Med. 2020;9(7):2095.
24. Raisi-Estabragh Z, McCracken C, Cooper J, et al. Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank. Aging Clin Exp Res. 2021;8:1-12.
25. Bahrami A, Parsamaneh N, Atkin SL, et al. Effect of statins on toll-like receptors: A new insight to pleiotropic effects. Pharmacol Res. 2018;135:230-238.
26. Reiner Z, Hatamipour M, Banach M, et al. Statins and the COVID-19 main protease: In silico evidence on direct interaction. Arch Med Sci. 2020;16:490-496.
27. Lala A, Johnson KW, Januzzi JL, et al. Mount Sinai COVID informatics center. prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76:533-546.
28. Elshafei MN, Khalil A, El-Bardissy A, et al. The efficacy of colchicine in the management of coronavirus disease 2019: Aprotivil for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(36):e21911.

How to cite this article: Saeed S, Mancia G. Arterial stiffness and COVID-19: A bidirectional cause-effect relationship. J Clin Hypertens. 2021;23:1099-1103. https://doi.org/10.1111/jch.14259